Ludovica Riera

Ludovica Riera

Auto-generated profile, based on publicly available information

Ludovica Riera

Department of Public Health and Microbiology, Medical School, Torino, Italy

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2011 in Journal of Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
ABAntonella Barreca
Antonella Barreca
ELElena Lasorsa
Elena Lasorsa
LRLudovica Riera
Ludovica Riera
RMRodolfo Machiorlatti
Rodolfo Machiorlatti
Roberto PivaRoberto Piva
Roberto Piva
GIGiorgio Inghirami
Giorgio Inghirami
The receptor tyrosine kinases (RTKs) play a critical role, controlling cell proliferation, survival, and differentiation of normal cells. Their pivotal function has been firmly established in the pathogenesis of many cancers as well. The anaplastic lymphoma kinase (ALK), a transmembrane RTK, originally identified in the nucleophosmin (NPM)–ALK chimera of anaplastic large cell lymphoma, has emerged as a novel tumorigenic player in several human cancers. In this review, we describe the expression of the ALK–RTK, its related fusion proteins, and their molecular mechanisms of activation. Novel tailored strategies are briefly illustrated for the treatment of ALK-positive neoplasms.

11 November 2009 in Cancer Research
Verified
Journal Article
Open access
PDF file
Chiara AmbrogioChiara Ambrogio
Chiara Ambrogio
CMCinzia Martinengo
Cinzia Martinengo
CVClaudia Voena
Claudia Voena
FTFabrizio Tondat
Fabrizio Tondat
LRLudovica Riera
Ludovica Riera
Roberto ChiarleRoberto Chiarle
Roberto Chiarle
Transformed cells in lymphomas usually maintain the phenotype of the postulated normal lymphocyte from which they arise. By contrast, anaplastic large cell lymphoma (ALCL) is a T-cell lymphoma with aberrant phenotype because of the defective expression of the T-cell receptor and other T-cell–specific molecules for still undetermined mechanisms. The majority of ALCL carries the translocation t(2;5) that encodes for the oncogenic tyrosine kinase NPM-ALK, fundamental for survival, proliferation, and migration of transformed T cells. Here, we show that loss of T-cell–specific molecules in ALCL cases is broader than reported previously and involves most T-cell receptor–related signaling molecules, including CD3ϵ, ZAP70, LAT, and SLP76. We further show that NPM-ALK, but not the kinase-dead NPM-ALKK210R, downregulated the expression of these molecules by a STAT3-mediated gene transcription regulation and/or epigenetic silencing because this downregulation was reverted by treating ALCL cells with 5-aza-2-deoxycytidine or by knocking down STAT3 through short hairpin RNA. Finally, NPM-ALK increased the methylation of ZAP70 intron 1-exon 2 boundary region, and both NPM-ALK and STAT3 regulated the expression levels of DNA methyltransferase 1 in transformed T cells. Thus, our data reveal that oncogene-deregulated tyrosine kinase activity controls the expression of molecules that determine T-cell identity and signaling. [Cancer Res 2009;69(22):8611–9]

1 May 2000 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
LRLudovica Riera
Ludovica Riera
Marisa GariglioMarisa Gariglio
Marisa Gariglio
GVGuido Valente
Guido Valente
AMArno Müllbacher
Arno Müllbacher
CMCrisan Museteanu
Crisan Museteanu
MSMarkus M. Simon
Markus M. Simon

1 December 2005 in Blood
Verified
Journal Article
Open access
PDF file
Chiara AmbrogioChiara Ambrogio
Chiara Ambrogio
CVClaudia Voena
Claudia Voena
AMAndrea D. Manazza
Andrea D. Manazza
Roberto PivaRoberto Piva
Roberto Piva
LRLudovica Riera
Ludovica Riera
Roberto ChiarleRoberto Chiarle
Roberto Chiarle
Translocations of the anaplastic lymphoma kinase (ALK) gene have been described in anaplastic large-cell lymphomas (ALCLs) and in stromal tumors. The most frequent translocation, t(2;5), generates the fusion protein nucleophosmin (NPM)–ALK with intrinsic tyrosine kinase activity. Along with transformation, NPM-ALK induces morphologic changes in fibroblasts and lymphoid cells, suggesting a direct role of ALK in cell shaping. In this study, we used a mass-spectrometry–based proteomic approach to search for proteins involved in cytoskeleton remodeling and identified p130Cas (p130 Crk-associated substrate) as a novel interactor of NPM-ALK. In 293 cells and in fibroblasts as well as in human ALK-positive lymphoma cell lines, NPM-ALK was able to bind p130Cas and to induce its phosphorylation. Both of the effects were dependent on ALK kinase activity and on the adaptor protein growth factor receptor–bound protein 2 (Grb2), since no binding or phosphorylation was found with the kinase-dead mutant NPM-ALKK210R or in the presence of a Grb2 dominant-negative protein. Phosphorylation of p130Cas by NPM-ALK was partially independent from Src (tyrosine kinase pp60c-src) kinase activity, as it was still detectable in Syf-/- cells. Finally, p130Cas-/- (also known as Bcar1-/-) fibroblasts expressing NPM-ALK showed impaired actin filament depolymerization and were no longer transformed compared with wild-type cells, indicating an essential role of p130Cas activation in ALK-mediated transformation.

30 October 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
CMCinzia Martinengo
Cinzia Martinengo
TPTeresa Poggio
Teresa Poggio
MMMatteo Menotti
Matteo Menotti
MSMaria Stella Scalzo
Maria Stella Scalzo
CMCristina Mastini
Cristina Mastini
Roberto ChiarleRoberto Chiarle
Roberto Chiarle
Rearrangements involving the anaplastic lymphoma kinase (ALK) gene are defining events in several tumors, including anaplastic large-cell lymphoma (ALCL) and non–small cell lung carcinoma (NSCLC). In such cancers, the oncogenic activity of ALK stimulates signaling pathways that induce cell transformation and promote tumor growth. In search for common pathways activated by oncogenic ALK across different tumors types, we found that hypoxia pathways were significantly enriched in ALK-rearranged ALCL and NSCLC, as compared with other types of T-cell lymphoma or EGFR- and K-RAS–mutated NSCLC, respectively. Consistently, in both ALCL and NSCLC, we found that under hypoxic conditions, ALK directly regulated the abundance of hypoxia-inducible factors (HIF), which are key players of the hypoxia response in normal tissues and cancers. In ALCL, the upregulation of HIF1α and HIF2α in hypoxic conditions required ALK activity and its downstream signaling proteins STAT3 and C/EBPβ. In vivo, ALK regulated VEGFA production and tumor angiogenesis in ALCL and NSCLC, and the treatment with the anti-VEGFA antibody bevacizumab strongly impaired ALCL growth in mouse xenografts. Finally, HIF2α, but not HIF1α, was required for ALCL growth in vivo whereas the growth and metastasis potential of ALK-rearranged NSCLC required both HIF1α and HIF2α. In conclusion, we uncovered an ALK-specific regulation of the hypoxia response across different ALK+ tumor types and propose HIFs as a powerful specific therapeutic target in ALK-rearranged ALCL and NSCLC. Cancer Res; 74(21); 6094–106. ©2014 AACR.

8 March 2000 in The Hematology Journal
Verified
Journal Article
Closed access
SLS Landolfo
S Landolfo
AGA Guarini
A Guarini
LRL Riera
L Riera
Marisa GariglioMarisa Gariglio
Marisa Gariglio
Giorgio GribaudoGiorgio Gribaudo
Giorgio Gribaudo
RFR Foa
R Foa